95%Confidence
3Views
FDASource
2026-03-02Date
Summary
Asteria Health's fifth recall for testosterone pellets demonstrates an ongoing, unresolved contamination crisis affecting their core product line. The company likely faces existential regulatory threats including possible injunction or permanent closure of manufacturing operations.
Actionable: Treat Asteria Health as non-viable until independent audits confirm complete remediation of their manufacturing quality systems.
AI Confidence: 95%
Data Points
firmF.H. INVESTMENTS, Inc. (dba Asteria Health)
classificationClass II
statusOngoing
distributionNationwide in the USA
productTestosterone, 87.5 mg, 1 Sterile Pellet, Asteria Health 432 Industrial Ln, Birmingham, AL 35211, NDC: 79559-1087-32.
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now